{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T01:03:20Z","timestamp":1747616600796,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"IPSEN Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s12325-018-0745-6","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T08:25:25Z","timestamp":1531124725000},"page":"1215-1231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient\u2013Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-1175","authenticated-orcid":false,"given":"Monika","family":"Wagner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dima","family":"Samaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Cuervo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshila","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"issue":"6","key":"745_CR1","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","volume":"128","author":"IM Modlin","year":"2005","unstructured":"Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717\u201351.","journal-title":"Gastroenterology"},{"issue":"5","key":"745_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3892\/mco.2014.332","volume":"2","author":"JM O\u2019Connor","year":"2014","unstructured":"O\u2019Connor JM, Marmissolle F, Bestani C, et al. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol. 2014;2(5):673\u201384.","journal-title":"Mol Clin Oncol"},{"issue":"11","key":"745_CR3","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/j.ejca.2013.02.029","volume":"49","author":"JM van der Zwan","year":"2013","unstructured":"van der Zwan JM, Trama A, Otter R, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013;49(11):2565\u201378.","journal-title":"Eur J Cancer"},{"issue":"9","key":"745_CR4","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/annonc\/mdq022","volume":"21","author":"R Garcia-Carbonero","year":"2010","unstructured":"Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794\u2013803.","journal-title":"Ann Oncol"},{"issue":"12","key":"745_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s12094-014-1214-6","volume":"16","author":"R Garcia-Carbonero","year":"2014","unstructured":"Garcia-Carbonero R, Jimenez-Fonseca P, Teule A, Barriuso J, Sevilla I. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Clin Transl Oncol. 2014;16(12):1025\u201334.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"745_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F, et al. Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172\u201385.","journal-title":"Neuroendocrinology"},{"issue":"28","key":"745_CR7","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol"},{"issue":"16","key":"745_CR8","first-page":"1556","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(16):1556\u20137.","journal-title":"N Engl J Med"},{"key":"745_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.zefq.2017.05.002","volume":"123\u2013124","author":"L Perestelo-Perez","year":"2017","unstructured":"Perestelo-Perez L, Rivero-Santana A, Alvarez-Perez Y, Alonso-Coello P, Orrego C, Serrano-Aguilar P. Shared decision making in Spain: supportive policies and research initiatives, trends and directions for future. Z Evid Fortbild Qual Gesundhwes. 2017;123\u2013124:85\u201390.","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"4","key":"745_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1017\/S0266462311000493","volume":"27","author":"F Izquierdo","year":"2011","unstructured":"Izquierdo F, Gracia J, Guerra M, Blasco JA, Andradas E. Health technology assessment-based development of a Spanish breast cancer patient decision aid. Int J Technol Assess Health Care. 2011;27(4):363\u20138.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"745_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.23938\/ASSN.0003","volume":"40","author":"N Padilla Garrido","year":"2017","unstructured":"Padilla Garrido N, Aguado CF, Ortega MM, Bayo CJ, Bayo LE. Shared decision making from the perspective of the cancer patient: participatory roles and evaluation of the process. An Sist Sanit Navar. 2017;40(1):25\u201333.","journal-title":"An Sist Sanit Navar"},{"issue":"1","key":"745_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12325-017-0653-1","volume":"35","author":"M Wagner","year":"2018","unstructured":"Wagner M, Samaha D, Khoury H, et al. Development of a framework based on reflective MCDA to support patient-clinician shared decision-making: the case of the management of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the United States. Adv Ther. 2018;35(1):81\u201399.","journal-title":"Adv Ther"},{"key":"745_CR13","unstructured":"EVIDEM Collaboration. Evidence and value: impact on decision making. 2015. https:\/\/www.evidem.org\/. Accessed 17 Sept 2015."},{"key":"745_CR14","unstructured":"Royal Institute of International Affairs. Chatham House Rule. 2002. https:\/\/www.chathamhouse.org\/about\/chatham-house-rule. Accessed 15 Sept 2015."},{"key":"745_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/1472-6963-11-329","volume":"11","author":"M Tony","year":"2011","unstructured":"Tony M, Wagner M, Khoury H, et al. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res. 2011;11:329.","journal-title":"BMC Health Serv Res"},{"key":"745_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1478-7547-12-22","volume":"12","author":"J van Til","year":"2014","unstructured":"van Til J, Groothuis-Oudshoorn C, Lieferink M, Dolan J, Goetghebeur M. Does technique matter; a pilot study exploring weighting techniques for a multi-criteria decision support framework. Cost Eff Resour Alloc. 2014;12:22.","journal-title":"Cost Eff Resour Alloc"},{"issue":"5","key":"745_CR17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1177\/2168479016642812","volume":"50","author":"MM Goetghebeur","year":"2016","unstructured":"Goetghebeur MM, Wagner M, Nikodem M, Zyla A, Micaleff A, Amzal B. Pragmatic multicriteria decision analysis (MCDA) combined with advanced pharmacoepidemiology for benefit-risk assessments of medicines adapted to the real-life constraints of regulators: development and case study. Ther Innov Regul Sci. 2016;50(5):620\u201331.","journal-title":"Ther Innov Regul Sci"},{"issue":"11","key":"745_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/15265161.2017.1378753","volume":"17","author":"PA Ubel","year":"2017","unstructured":"Ubel PA, Scherr KA, Fagerlin A. Empowerment failure: how shortcomings in physician communication unwittingly undermine patient autonomy. Am J Bioeth. 2017;17(11):31\u20139.","journal-title":"Am J Bioeth"},{"issue":"12","key":"745_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nrd4129","volume":"12","author":"HG Eichler","year":"2013","unstructured":"Eichler HG, Bloechl-Daum B, Brasseur D, et al. The risks of risk aversion in drug regulation. Nat Rev Drug Discov. 2013;12(12):907\u201316.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"745_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-016-0444-9","volume":"11","author":"T Morel","year":"2016","unstructured":"Morel T, Ayme S, Cassiman D, Simoens S, Morgan M, Vandebroek M. Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers. Orphanet J Rare Dis. 2016;11(1):70.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"745_CR21","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/S1470-2045(14)71153-2","volume":"16","author":"D Ashley","year":"2015","unstructured":"Ashley D, Thomas D, Gore L, et al. Accepting risk in the acceleration of drug development for rare cancers. Lancet Oncol. 2015;16(4):e190\u20134.","journal-title":"Lancet Oncol"},{"issue":"3","key":"745_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med"},{"key":"745_CR23","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. Cartera de servicios comunes de prestaci\u00f3n farmac\u00e9utica. 2017. https:\/\/www.msssi.gob.es\/profesionales\/CarteraDeServicios\/ContenidoCS\/5PrestacionFarmaceutica\/PF-PrestacionFarmaceutica.htm. Accessed 19 Jan 2017."},{"key":"745_CR24","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. Cartera de servicios comunes de atenci\u00f3n especializada. 2017. https:\/\/www.msssi.gob.es\/profesionales\/CarteraDeServicios\/ContenidoCS\/3AtencionEspecializada\/home.htm. Accessed 19 Jan 2017."},{"issue":"Suppl 1","key":"745_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3111\/13696998.2012.720319","volume":"15","author":"R Casciano","year":"2012","unstructured":"Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Garrison LP. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. J Med Econ. 2012;15(Suppl 1):55\u201364.","journal-title":"J Med Econ"},{"issue":"3","key":"745_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/ERC-15-0490","volume":"23","author":"ME Caplin","year":"2016","unstructured":"Caplin ME, Pavel M, Cwikla JB, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191\u20139.","journal-title":"Endocr Relat Cancer"},{"key":"745_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2147\/PPA.S34337","volume":"6","author":"V Johanson","year":"2012","unstructured":"Johanson V, Wilson B, Abrahamsson A, et al. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(\u00ae) given by either self\/partner or a health care professional. Patient Prefer Adherence. 2012;6:703\u201310.","journal-title":"Patient Prefer Adherence"},{"key":"745_CR28","unstructured":"Ipsen Pharma Biotech. Prescribing information. Somatuline depot. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022074s011lbl.pdf. Accessed 29 June 2018."},{"key":"745_CR29","first-page":"103","volume":"5","author":"DT Adelman","year":"2012","unstructured":"Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl). 2012;5:103\u20139.","journal-title":"Med Devices (Auckl)"},{"key":"745_CR30","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Neuroendocrine tumors. Version 1.2015. 2014. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed 12 Nov 2015."},{"issue":"3","key":"745_CR31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"JL Beaumont","year":"2012","unstructured":"Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461\u20136.","journal-title":"Pancreas"},{"issue":"4","key":"745_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3111\/13696998.2012.670175","volume":"15","author":"P Swinburn","year":"2012","unstructured":"Swinburn P, Wang J, Chandiwana D, Mansoor W, Lloyd A. Elicitation of health state utilities in neuroendocrine tumours. J Med Econ. 2012;15(4):681\u20137.","journal-title":"J Med Econ"},{"key":"745_CR33","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. BOLET\u00cdN OFICIAL DEL ESTADO. No. 185. I. Disposiciones generales. 2016."},{"key":"745_CR34","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. BOLET\u00cdN OFICIAL DEL ESTADO. No. 226. I. Disposiciones generales. Octreotide. 2016."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0745-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:29:06Z","timestamp":1724412546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0745-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0745-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2018,7,9]]},"assertion":[{"value":"10 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}